Sorrento Therapeutics Boom List
- Fortune Bio (Sorrento Manufacturer in China) Posted a video of Covi-Stix being made with CE approval certificate and Respi-Stix listed for sale. http://www.fortunetest.com/
- ARD-301 Acquired from Aardvark for Treatment of Long Covid. Ph2 already approved to proceed
- STI-6643 Ph1 Trial approved for multiple cancer type treatments “Basket Trial”
- Sorrento Therapeutics entered into an Exclusive Licensing Term Sheet with Aardvark Therapeutics to Acquire Its ARD-301 For the Treatment of Chronic Pain, Fibromyalgia, and Chronic Long Haul Covid Syndrome
- On February 24, 2021, Sorrento Therapeutics acquire ANP Technologies- PR to follow!
- Lee's Pharmaceutical Announces Its Anti-PD-L1 Antibody Socazolimab, licensed from Sorrento Therapeutics, Receives Breakthrough Therapy Designation in China for the Treatment of Recurrent or Metastatic Cervical Cancer
- Subsidiary Company - ADNAB, Inc. - to Develop and Commercialize ADNAB™ Platform Products for Haematological Malignancies and Solid Tumours Based on an Exclusive Technology License from the Mayo Clinic- Multiple IND's in 2021
- DARPA sponsoring three new phase 2 trials of COVI-AMG being delivered to 1000 patients. STI2020 is a refined version of 1499 with increased potency and requires smaller dosage.
- Feb 4- New COVI-MSC trial starting. Phase 1b tests 100% patients recovered from mechanical ventilation and leaving hospital after a week!!! Phase 2 trials starting to enrol 100 patients
- Rheumatoid Arthritis pain relief using Sofusa DoseConnect started Ph1b trial Jan 2021. Drug already approved - this is all about the delivery. Expect rapid results and a massive market.
- Abivertinib - Cures Covid at late stages by reducing immune overload (cytokine storm). Stage 2 trials in progress in US and Brazil nearing completion. Over 50% of patients discharged in a placebo controlled test. Very unlikely it is the 50% on placebo so when results unblinded Feb 4- Trials increased to 5 hospitals (Feb 11- 75% enrolled, results due by March 11)- Israel announced they have repurposed a cancer drug with similar positive response.
- Jan 2021 BlackRock increased stake in Sorrento massively and now hold 6.7% of all stock!
- STI-2020 PR Confirmed it preserves Binding Against UK and SA Covid mutations
- Covi-Stix being mass produced. UPS Air crew trialling the product. (CVS Pharmacy rumoured to have ordered 75 million).
- RESPI-STIX patent applied for Jan 16 to create combination test for antibody and current viruses including Covid, Flu A and B - Manufacturing at Zhengzhou Fortune Bioscience Co
- Looks like we have won a court case with PSS for Cynviloq cancer drug he bought from us. We now have the drug back in our pipeline and expecting $1bn compensation to follow.
- Last year we acquired multiple companies. We own 25% of Celulatory who are listing for approx. $2bn due to merger with GX Acquisition Corp
- Covi-Drops STI2099 (Refined version of 1499) nasal antibody spray kills all Covid in early stages and can be administered in doctors surgery, maybe at home. PH1b FDA approved March 2
- Covi-GUARD STI1499 Antibody which kills 100% of Covid. Rumoured this has been licenced or sold to a big player for $2bn.
- 11 Covid programs in progress with strong potential- Vaccines removed from pipeline to focus on these, however T-VIVIA-19 could come back to beat mutations if others fail.
- Multiple cancer and pain relief plays which triggered BO offers of $7 a year ago before we started developing for Covid.
- Yes, we only have one drug approved (ZTildo) but sales are growing massively
- We own 10 million shares of Immunity Bio. They are merging with NK in June PSS is chairman making it more likely our Cynviloq case will be settled before then! $$ NK SP Surging
- Four analysts have us at $20-35 which is very conservative.
- Testing Lab approved in California for Covid (will speed up in house testing and provide source of revenue)
- DARPA funding of at least $34m to bring STI 2020 to the end of P2 trials and beyond
- CEO gets share options if he maintains SP above $17-130 for six consecutive months
- We have been heavily shorted due to a scam by Hindenburg (top 30 most shorted) and now we are poised for a massive short squeeze.
- ACEA acquisition due for completion - announcement imminent
- SP-102 Ph3 trial results-potentially the first FDA approved epidural steroid product for the treatment of sciatica (massive market) Due by end of March
- NDA in China for Abivertinib for NSCLC
- Significant recruitment in manufacturing roles over Q4 2020 and Q1 2021